lorviqua
pfizer europe ma eeig - lorlatinib - carcinom, non-small cell lung - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
orserdu
stemline therapeutics b.v. - elacestrant - bröst-neoplasmer - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
lapatinib newbury 250 mg filmdragerad tablett
newbury pharmaceuticals ab - lapatinibditosilatmonohydrat - filmdragerad tablett - 250 mg - lapatinibditosilatmonohydrat 405 mg aktiv substans
erlotinib mylan 100 mg filmdragerad tablett
mylan ab - erlotinibhydroklorid - filmdragerad tablett - 100 mg - erlotinibhydroklorid 109,27 mg aktiv substans; laktosmonohydrat hjälpämne
erlotinib mylan 150 mg filmdragerad tablett
mylan ab - erlotinibhydroklorid - filmdragerad tablett - 150 mg - erlotinibhydroklorid 163,9 mg aktiv substans; laktosmonohydrat hjälpämne
erlotinib glenmark 25 mg filmdragerad tablett
glenmark arzneimittel gmbh - erlotinibhydroklorid - filmdragerad tablett - 25 mg - erlotinibhydroklorid 27,32 mg aktiv substans; laktosmonohydrat hjälpämne
erlotinib glenmark 150 mg filmdragerad tablett
glenmark arzneimittel gmbh - erlotinibhydroklorid - filmdragerad tablett - 150 mg - erlotinibhydroklorid 163,9 mg aktiv substans; laktosmonohydrat hjälpämne
erlotinib sandoz 25 mg filmdragerad tablett
sandoz a/s - erlotinibhydroklorid - filmdragerad tablett - 25 mg - erlotinibhydroklorid 27,32 mg aktiv substans; laktosmonohydrat hjälpämne
erlotinib sandoz 150 mg filmdragerad tablett
sandoz a/s - erlotinibhydroklorid - filmdragerad tablett - 150 mg - erlotinibhydroklorid 163,9 mg aktiv substans; laktosmonohydrat hjälpämne
erlotinib stada 100 mg filmdragerad tablett
stada arzneimittel ag - erlotinibhydroklorid - filmdragerad tablett - 100 mg - erlotinibhydroklorid 109,27 mg aktiv substans; laktosmonohydrat hjälpämne